Top

Published in:

01-01-2016 | Original Article

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Authors: Danay Saavedra, Beatriz García, Patricia Lorenzo-Luaces, Amnely González, Xitlally Popa, Karla P. Fuentes, Zaima Mazorra, Tania Crombet, Elia Neninger, Agustin Lage

Published in: Cancer Immunology, Immunotherapy | Issue 1/2016

Abstract

Purpose

There are well-known alterations occurring within the immune system with aging. Collectively, these changes are known as immunosenescence. The incidence of malignancies also increases with age. The aim of this study was to determine the presence of immunosenescence biomarkers in non-small cell lung cancer (NSCLC) patients and to evaluate some of them as predictive biomarkers of CIMAvax-EGF cancer vaccine efficacy.

Methods

Sixty-six NSCLC patients, vaccinated or not with CIMAvax-EGF cancer vaccine, and 37 age-matched controls were enrolled. Peripheral blood samples were studied for CD19+, CD4+, CD8+, CD28−, CD57+ and CD45RA+ subpopulations by flow cytometry.

Results

Absolute count of CD19+ and the CD4/CD8 ratio were significantly lower in NSCLC patients than in age-paired controls, while highly differentiated T cells increased in NSCLC patients treated with platinum-based chemotherapy. Using Cox regression, we were able to dichotomize the patient population according to biomarkers. Vaccinated patients with frequency <24 % of CD8 + CD28− T cells, >40 % of CD4 T cells and CD4/CD8 ratio higher than two at the beginning of immunotherapy achieved a 20-month increase in median survival regarding control patients.

Conclusions

Distribution of lymphocyte subsets was influenced by cancer and chemotherapy in NSCLC patients. CD19 + B cells decrease by cancer disease and not by chemotherapy, and CD28− subpopulations increase by chemotherapy and not by cancer. The proportion of CD8 + CD28− T cells, CD4+ T cells and CD4/CD8 ratio can be used as predictive biomarkers of CIMAvax-EGF efficacy in NSCLC patients and thereby could, be a useful tool for a personalized treatment.

Fulop T, Larbi A, Kotb R, Pawelec G (2013) Immunology of aging and cancer development. Interdiscip Top Gerontol 38:38–48. doi:10.1159/000343599 PubMedCrossRef

Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G (2011) Aging, immunity, and cancer. Discov Med 11:537–550PubMed

Lang PO, Govind S, Aspinall R (2013) Reversing T cell immunosenescence: why, who, and how. Age 35:609–620. doi:10.1007/s11357-012-9393-y PubMedPubMedCentralCrossRef

Pawelec G (2014) Immunosenenescence: role of cytomegalovirus. Exp Gerontol 54:1–5. doi:10.1016/j.exger.2013.11.010 PubMedCrossRef

Pawelec G (2012) Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing 9:15. doi:10.1186/1742-4933-9-15 PubMedPubMedCentralCrossRef

Falci C, Gianesin K, Sergi G, Giunco S, De Ronch I, Valpione S et al (2013) Immune senescence and cancer in elderly patients: results from an exploratory study. Exp Gerontol 48:1436–1442. doi:10.1016/j.exger.2013.09.011 PubMedCrossRef

Mazzola P, Radhi S, Mirandola L, Annoni G, Jenkins M, Cobos E, Chiriva-Internati M (2012) Aging, cancer, and cancer vaccines. Immun Ageing 9:4. doi:10.1186/1742-4933-9-4 PubMedPubMedCentralCrossRef

Chen IH, Lai YL, Wu CL, Chang YF, Chu CC, Tsai IF, Sun FJ, Lu YT (2010) Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection. Cancer Immunol Immunother 59:323–334. doi:10.1007/s00262-009-0753-0 PubMedCrossRef

Verdecia BG, Hernández DS, Lorenzo-Luaces P, Alvarez TDJB, Rupalé IL, Herrera ZM, Ramos TC, Dávila AL (2013) Immunosenescence and gender: a study in healthy Cubans. Immun Ageing 10(1):16. doi:10.1186/1742-4933-10-16 CrossRef

10.

Gonzalez G, Diaz-Miqueli A, Crombet T, Raez LE, Lage A (2013) Current algorithm for treatment of advanced NSCLC patients: How to include active immunotherapy? J Cancer Ther 4(8A):59–75. doi:10.4236/jct.2013.48A010 CrossRef

11.

Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, González Dueñas M, Viada C, García Verdecia B, Crombet Ramos T, González Marinello G, Lage Dávila A (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26(9):1452–1458. doi:10.1200/JCO.2007.11.5980 PubMedCrossRef

12.

Fulop T, Larbi A, Witkowski JM, Kotb R, Hirokawa K, Pawelec G (2013) Immunosenescence and cancer. Crit Rev Oncog 18:489–513PubMedCrossRef

13.

Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R, Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, Soares MV, Akbar AN (2011) Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4 + CD45RA + CD27+ T cells: the potential involvement of interleukin-7 in this process. Immunology 132:326–339. doi:10.1111/j.1365-2567.2010.03386.x PubMedPubMedCentralCrossRef

14.

Appay V, Sauce D, Prelog M (2010) The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals. Aging 2:78–81PubMedPubMedCentral

15.

Appay V, van Lier RA, Sallusto F, Roederer M (2008) Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 73:975–983. doi:10.1002/cyto.a.20643 PubMedCrossRef

16.

Larbi A, Fulop T (2014) From “truly naive” to “exhausted senescent” T cells: when markers predict functionality. Cytom A 85:25–35. doi:10.1002/cyto.a.22351 CrossRef

17.

Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, Viada C, Gonzalez G, Mazorra Z, Lage A, Crombet T (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:840–846. doi:10.1158/1078-0432.CCR-07-1050 PubMedCrossRef

18.

Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A (2010) Potential role of immunosenescence in cancer development. Ann NY Acad Sci 1197:158–165. doi:10.1111/j.1749-6632.2009.05370.x PubMedCrossRef

19.

Gravekamp C (2011) The impact of aging on cancer vaccination. Curr Opin Immunol 23:555–560. doi:10.1016/j.coi.2011.05.003 PubMedPubMedCentralCrossRef

20.

Pritz T, Weinberger B, Grubeck-Loebenstein B (2014) The aging bone marrow and its impact on immune responses in old age. Immunol Lett 162(1 Pt B):310–315. doi:10.1016/j.imlet.2014.06.016 PubMedCrossRef

21.

Fulop T, Montgomery RR (2014) Editorial overview: immune senescence: known knowns and unknown unknowns. Curr Opin Immunol 29:7–9. doi:10.1016/j.coi.2014.06.005 CrossRef

22.

Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG (2000) Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 121:187–201PubMedCrossRef

23.

Strindhall J, Skog M, Ernerudh J, Bengner M, Lofgren S, Matussek A, Nilsson BO, Wikby A (2013) The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age 35:985–991. doi:10.1007/s11357-012-9400-3 PubMedPubMedCentralCrossRef

24.

Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41:245–251. doi:10.1042/BST20120265 PubMedPubMedCentralCrossRef

25.

Akbar AN, Henson SM (2011) Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 11:289–295. doi:10.1038/nri2959 PubMedCrossRef

26.

Derhovanessian E, Maier AB, Hahnel K, Beck R, de Craen AJ, Slagboom EP, Westendorp RG, Pawelec G (2011) Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol 92:2746–2756. doi:10.1099/vir.0.036004-0 PubMedCrossRef

27.

McElhaney JE, Effros RB (2009) Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 21:418–424. doi:10.1016/j.coi.2009.05.023 PubMedPubMedCentralCrossRef

28.

Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, Lago LD, Repetto L, Ring A, Wildiers H (2014) Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriatr Oncol 5:204–218. doi:10.1016/j.jgo.2013.09.001 PubMedCrossRef

29.

Chang S, Kohrt H, Maecker HT (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713–719. doi:10.1007/s00262-014-1521-3 PubMedPubMedCentralCrossRef

30.

Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED, Gastineau DA, Dietz AB (2013) Immune monitoring using the predictive power of immune profiles. J Immunother Cancer 1:7. doi:10.1186/2051-1426-1-7 PubMedPubMedCentralCrossRef

31.

Kelloff GJ, Sigman CC (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11:201–214. doi:10.1038/nrd3651 PubMedCrossRef

32.

Lima L, Oliveira D, Ferreira JA, Tavares A, Cruz R, Medeiros R, Santos L (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int 116(5):753–63. doi:10.1111/bju.12844 PubMedCrossRef

Title: Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
Authors: Danay Saavedra
Beatriz García
Patricia Lorenzo-Luaces
Amnely González
Xitlally Popa
Karla P. Fuentes
Zaima Mazorra
Tania Crombet
Elia Neninger
Agustin Lage
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 1/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1773-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

Cholesterol metabolites and tumor microenvironment: the road towards clinical translation

Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORγt, decreases murine spontaneous intestinal tumorigenesis

Phloretin increases the anti-tumor efficacy of intratumorally delivered heat-shock protein 70 kDa (HSP70) in a murine model of melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer